# Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

> **NCT00916123** · PHASE1 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 15 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Prednisone
- **DRUG:** 177Lu-J591
- **DRUG:** 177Lu-J591
- **DRUG:** 177Lu-J591
- **DRUG:** 177Lu-J591
- **DRUG:** 177Lu-J591

## Key facts

- **NCT ID:** NCT00916123
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2015-12
- **Final completion:** 2018-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00916123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00916123, "Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00916123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*